Peer-influenced content. Sources you trust. No registration required. This is HCN.

Clinical Advances in Hematology & OncologyJAK Inhibitors in the Treatment of Myelofibrosis

JAK inhibitors provide a relatively tolerable drug option for controlling symptoms, reducing splenomegaly, and improving quality of life, but often at the expense of worsening cytopenias and without halting disease progression or preventing leukemic transformation. In this article, the authors review FDA–approved JAK inhibitors as well as those in late-phase clinical trials, and provide a schema for choosing among the available options for patients with MF.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form